Kolon Life Science Inc. (KOSDAQ: 102940)
South Korea flag South Korea · Delayed Price · Currency is KRW
17,900
+540 (3.11%)
Nov 15, 2024, 9:00 AM KST

Kolon Life Science Statistics

Total Valuation

Kolon Life Science has a market cap or net worth of KRW 221.01 billion. The enterprise value is 320.54 billion.

Market Cap 221.01B
Enterprise Value 320.54B

Important Dates

The last earnings date was Thursday, November 14, 2024.

Earnings Date Nov 14, 2024
Ex-Dividend Date n/a

Share Statistics

Kolon Life Science has 12.42 million shares outstanding. The number of shares has increased by 0.46% in one year.

Current Share Class n/a
Shares Outstanding 12.42M
Shares Change (YoY) +0.46%
Shares Change (QoQ) +0.97%
Owned by Insiders (%) 18.06%
Owned by Institutions (%) 0.18%
Float 6.94M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 1.45
PB Ratio 1.72
P/TBV Ratio n/a
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings -3.80
EV / Sales 2.29
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF -8.09

Financial Position

The company has a current ratio of 0.62, with a Debt / Equity ratio of 0.98.

Current Ratio 0.62
Quick Ratio 0.33
Debt / Equity 0.98
Debt / EBITDA n/a
Debt / FCF -3.16
Interest Coverage -3.38

Financial Efficiency

Return on equity (ROE) is -58.21% and return on invested capital (ROIC) is -5.73%.

Return on Equity (ROE) -58.21%
Return on Assets (ROA) -4.33%
Return on Capital (ROIC) -5.73%
Revenue Per Employee 333.19M
Profits Per Employee -200.21M
Employee Count 421
Asset Turnover 0.41
Inventory Turnover 2.20

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -33.21% in the last 52 weeks.

Beta (5Y) n/a
52-Week Price Change -33.21%
50-Day Moving Average 18,899.20
200-Day Moving Average 21,670.80
Relative Strength Index (RSI) 39.21
Average Volume (20 Days) 15,248

Short Selling Information

Short Interest n/a
Short Previous Month n/a
Short % of Shares Out n/a
Short % of Float n/a
Short Ratio (days to cover) n/a

Income Statement

In the last 12 months, Kolon Life Science had revenue of KRW 140.27 billion and -84.29 billion in losses. Loss per share was -7,367.96.

Revenue 140.27B
Gross Profit 13.24B
Operating Income -23.80B
Pretax Income -84.26B
Net Income -84.29B
EBITDA -15.35B
EBIT -23.80B
Loss Per Share -7,367.96
Full Income Statement

Balance Sheet

The company has 25.56 billion in cash and 125.10 billion in debt, giving a net cash position of -99.53 billion or -8,011.65 per share.

Cash & Cash Equivalents 25.56B
Total Debt 125.10B
Net Cash -99.53B
Net Cash Per Share -8,011.65
Equity (Book Value) 127.77B
Book Value Per Share 10,361.31
Working Capital -68.85B
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -29.78 billion and capital expenditures -9.83 billion, giving a free cash flow of -39.60 billion.

Operating Cash Flow -29.78B
Capital Expenditures -9.83B
Free Cash Flow -39.60B
FCF Per Share -3,187.89
Full Cash Flow Statement

Margins

Gross margin is 9.44%, with operating and profit margins of -16.97% and -60.09%.

Gross Margin 9.44%
Operating Margin -16.97%
Pretax Margin -60.07%
Profit Margin -60.09%
EBITDA Margin -10.95%
EBIT Margin -16.97%
FCF Margin -28.23%

Dividends & Yields

Kolon Life Science does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -0.46%
Shareholder Yield -0.46%
Earnings Yield -41.42%
FCF Yield -17.92%

Stock Splits

The last stock split was on December 27, 2017. It was a forward split with a ratio of 1.5.

Last Split Date Dec 27, 2017
Split Type Forward
Split Ratio 1.5

Scores

Kolon Life Science has an Altman Z-Score of -0.07. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -0.07
Piotroski F-Score n/a